Photo by ThisisEngineering RAEng on Unsplash

Sherlock and Tolo create CRISPR agreement

Sherlock Biosciences gains exclusive rights to Tolo Biotech’s Cas12 technology
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

CAMBRIDGE, Mass. & SHANGHAI—Sherlock Biosciences announced today that it has entered into exclusive license agreements with Shanghai-based Tolo Biotech.

Tolo Biotech has granted Sherlock exclusive U.S. rights to its CRISPR-Cas12 diagnostic technology, including Cas12a and Cas12b. For its part, Sherlock granted Tolo exclusive rights to the CRISPR-Cas13 SHERLOCK diagnostic platform in Greater China. The financial details of the arrangement were not disclosed.

“We are very pleased to enter this agreement with Tolo, which complements Sherlock’s diagnostic rights to the Cas12 and Cas13 proteins licensed from the Broad Institute. With the addition of these exclusive Cas12 rights to Sherlock’s IP portfolio, as well as partnering with Tolo as our exclusive partner in China, we have secured our position as the global leader in CRISPR diagnostics,” said Rahul Dhanda, co-founder, president and chief executive officer of Sherlock Biosciences. 

“The advent of CRISPR technology is ushering in the next generation of molecular diagnostics. This agreement with Sherlock will enable both companies to develop diagnostic tools that can detect multiple pathogens or targets, improving disease screening, precision medicine and beyond,” added Jin Wang, co-founder and chief science officer of Tolo Biotech. “Tolo highly values this opportunity for close collaboration with Sherlock to promote the development of CRISPR diagnostics.”

The SHERLOCK diagnostic platform can achieve single molecule detection of nucleic acid targets. SHERLOCK utilizes CRISPR activity for “smart amplicon detection,” and it can be adapted for use with existing diagnostic instruments.This improves time to result, due to its significant multiplexing capacity. When a specific sequence of DNA or RNA is present, a CRISPR enzyme is activated and starts cutting nearby genetic material, releasing a fluorescent signal that indicates a positive result. 

In May, Sherlock received Emergency Use Authorization for its Sherlock CRISPR SARS-CoV-2 kit — the first FDA-authorized use of CRISPR technology.

“During what is a major healthcare crisis across the globe, we are heartened that the first FDA-authorized use of CRISPR will aid in the fight against this global COVID-19 pandemic,” noted James J. Collins, co-founder and board member of Sherlock Biosciences and Termeer Professor of Medical Engineering and Science for MIT’s Institute for Medical Engineering and Science (IMES) and the Department of Biological Engineering.

Access to rapid diagnostics is critical in combatting the COVID-19 pandemic, and it’s a primary focus for Sherlock Biosciences co-founder and board member, David R. Walt, Ph.D., who co-leads the Mass General Brigham Center for COVID Innovation.

“SHERLOCK enables rapid identification of a single alteration in a DNA or RNA sequence in a single molecule,” Walt stated. “That precision, coupled with its capability to be deployed to multiplex over 100 targets or as a simple point-of-care system, will make it a critical addition to the arsenal of rapid diagnostics already being used to detect COVID-19.”

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue